Is metformin an alternative to a GLP-1?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2027
Short answer
Not for weight loss. In the Diabetes Prevention Program, metformin produced about 2.7 percent weight loss at one year and around 2 percent sustained over a decade. Semaglutide produced 14.9 percent at 68 weeks and tirzepatide 20.2 percent at 72 weeks. Metformin is a good drug for insulin resistance, prediabetes and PCOS, and a weak one for weight.
Metformin and GLP-1 medications are often discussed as if they were two options for the same job. They are not. Metformin is not approved for weight management in the United States, and its effect on weight is modest and slow. It has other virtues that matter, particularly in insulin resistance and prediabetes.
How much weight metformin actually produces
The Diabetes Prevention Program remains the best long-term evidence. In the blinded phase, participants on metformin lost 2.7 percent of body weight at one year against 0.43 percent on placebo. Across the long-term follow-up, weight loss remained significantly greater on metformin than placebo but small in absolute terms, 2.0 percent versus 0.2 percent, and it was strongly related to adherence: the most adherent participants averaged 3.5 percent. That is a real effect and it is durable. It is also roughly a seventh of what tirzepatide produced in SURMOUNT-5.
| Medication | Mean weight loss | Trial and timepoint |
|---|---|---|
| Metformin | 2.7 percent | Diabetes Prevention Program, 1 year |
| Metformin, long term | About 2 percent | DPPOS follow-up |
| Semaglutide 2.4 mg | 14.9 percent | STEP 1, 68 weeks |
| Tirzepatide | 20.2 percent | SURMOUNT-5, 72 weeks |
Where metformin earns its place
Metformin lowers hepatic glucose output and improves insulin sensitivity. In the Diabetes Prevention Program it reduced progression from prediabetes to type 2 diabetes, and it remains a reasonable choice for that purpose, particularly in younger adults and in women with a history of gestational diabetes. It is widely used in polycystic ovary syndrome for its metabolic effects. It is inexpensive, has decades of safety data, and does not carry the boxed warning that GLP-1 medications carry.
Can they be used together
Yes, and they frequently are, particularly in type 2 diabetes where metformin is standard therapy and a GLP-1 is added for glucose and weight. The 2026 ADA standards make a GLP-1 receptor agonist or a dual GIP and GLP-1 agonist the preferred obesity medication for people with type 2 diabetes or cardiovascular disease. Combining them is not a compromise; it treats two different mechanisms.
If metformin has been offered to you for weight and nothing else, ask what the actual target is. If the target is prediabetes, insulin resistance or PCOS, it is a defensible first step. If the target is 15 percent weight loss, it will not get you there, and a plan built on it will stall.
The clinical detail
Diabetes Prevention Program: metformin 850 mg twice daily produced 2.7 plus or minus 4.7 percent weight loss at year 1 versus 0.43 plus or minus 4.7 percent on placebo. Through unblinded long-term follow-up, weight loss remained greater with metformin than placebo at 2.0 versus 0.2 percent, with a clear adherence gradient reaching 3.5 percent in the most adherent. Metformin is not FDA approved for chronic weight management. Comparators: semaglutide 2.4 mg minus 14.9 percent at 68 weeks (STEP 1); tirzepatide minus 20.2 percent at 72 weeks (SURMOUNT-5). Common metformin adverse effects are gastrointestinal and dose related; long-term use is associated with vitamin B12 malabsorption, making periodic B12 measurement reasonable.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2027
Sources
- Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. PMID 22442396
- STEP 1: Semaglutide Treatment Effect in People With Obesity. American College of Cardiology. PMID 33567185
- SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide. American College of Cardiology. doi:10.1056/NEJMoa2416394
- 2026 ADA Standards of Care: Obesity and Weight Management recommendations. American Diabetes Association via Guideline Central
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.